A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
About this study
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
- Stage IB and above non-small cell lung cancer or metastatic lung cancer
- Age >18 years old
- Willing and able to consent to study
- No prior history of neoadjuvant therapy.
- Age <18 years old
- Unable to provide consent
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Dennis Wigle, M.D., Ph.D.
Closed for enrollment